// App-Quantinova.ai

: Eligibility for anti-fibrotic therapy of patients in British Thoracic Society (BTS UK IPF Registry varies according to the reference values used to calculate FVC

Researchers

Presenter

  • Phil Molyneaux

Principal Investigators

  • Maria Loughenbury

  • Sally Welham

  • John Hutchinson

  • Huzaifa Adamali

  • Ahmed Fahim

  • Sarah Agnew

  • Wendy Funston

  • Sarah Haney

  • Ling-Pei Ho

  • Jack Richardson

  • Howard Almond

  • Steve Jones

  • Lisa Nicol

  • Katherine Spinks

  • Andrew Wilson

  • Lisa Spencer

Medical Centers

  • Imperial College, London, United Kingdom

  • British Thoracic Society, London, United Kingdom

  • King's Mill Hospital, Mansfield, United Kingdom

  • Southmead Hospital, Bristol, United Kingdom

  • New Cross Hospital, Wolverhampton, United Kingdom

  • Aintree University Hospital, Liverpool, United Kingdom

  • Queen Elizabeth Hospital, Coventry, United Kingdom

  • Wansbeck General Hospital, Ashington, United Kingdom

  • Churchill Hospital, Oxford, United Kingdom

  • SarcoidosisUK, London, United Kingdom

  • Action for Pulmonary Fibrosis, Bury St Edmunds, United Kingdom

  • Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

  • Lymington New Forest Hospital, Lymington, United Kingdom

  • Norwich Medical School, Norwich, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved